To compare the effects of polysaccharide nucleic acid fraction of bacillus calmette guerin (BCG PSN) and thymopeptides on T lymphocytes of normal and immunosuppressed mice, CD4 + and CD8 + T lymphocyte subsets of...To compare the effects of polysaccharide nucleic acid fraction of bacillus calmette guerin (BCG PSN) and thymopeptides on T lymphocytes of normal and immunosuppressed mice, CD4 + and CD8 + T lymphocyte subsets of single nucleic cell in thymus, spleen and peripheral blood were detected successively by flow cytometry after application of BCG PSN and thymopeptides. Meanwhile, CD4 +/CD8 + ratio was also calculated. The results showed that both BCG PSN and thymopeptides could decrease the proportion of CD4 + CD8 + T lymphocyte subsets in the thymus, at the same time increase CD4 + T lymphocyte, CD8 +T lymphocyte proportion in the three tissues. The fluctuation in amplitude was greater in thymopeptides group than that in BCG PSN group. It is concluded that acting location of thymopeptides is in thymus, its stimulating action is stronger than that of BCG PSN, while BCG PSN not only accelerates the differentiation in thymus, but also has some direct stimulation to peripheral CD4 +T lymphocytes, and can maintain CD4 +/CD8 + ratio within normal range. So, BCG PSN is safer.展开更多
Objective: To study the effect of Thymosin Injection combined with entecavir therapy on the viral load, liver fibrosis and immune response of patients with compensated liver cirrhosis. Methods: Patients who were diagn...Objective: To study the effect of Thymosin Injection combined with entecavir therapy on the viral load, liver fibrosis and immune response of patients with compensated liver cirrhosis. Methods: Patients who were diagnosed with chronic hepatitis b complicated by compensated liver cirrhosis in our hospital between March 2015 and January 2017 were selected and randomly divided into two groups, observation group received Thymosin Injection combined with entecavir therapy, and control group received entecavir therapy. The viral load, liver function injury indexes, liver fibrosis indexes, immune cytokines and immune cell apoptosis molecules were measured 24 weeks after treatment. Results: 24 weeks after treatment, HBV-DNA copy number in peripheral blood as well as ALT, AST, TBIL, HA, PC-III, LN, C-IV, IL-4, IL-10, TGF-β1, IL-17 and IL-22 levels in serum of observation group was significantly lower than those of control group, and peripheral blood FAS, CYCS, CASP8, CASP9 and CASP3 mRNA expression were significantly lower than those of control group. Conclusion:Thymosin Injection combined with entecavir therapy can reduce viral load, improve liver function, inhibit liver fibrosis and regulate immune function in patients with compensated liver cirrhosis.展开更多
文摘To compare the effects of polysaccharide nucleic acid fraction of bacillus calmette guerin (BCG PSN) and thymopeptides on T lymphocytes of normal and immunosuppressed mice, CD4 + and CD8 + T lymphocyte subsets of single nucleic cell in thymus, spleen and peripheral blood were detected successively by flow cytometry after application of BCG PSN and thymopeptides. Meanwhile, CD4 +/CD8 + ratio was also calculated. The results showed that both BCG PSN and thymopeptides could decrease the proportion of CD4 + CD8 + T lymphocyte subsets in the thymus, at the same time increase CD4 + T lymphocyte, CD8 +T lymphocyte proportion in the three tissues. The fluctuation in amplitude was greater in thymopeptides group than that in BCG PSN group. It is concluded that acting location of thymopeptides is in thymus, its stimulating action is stronger than that of BCG PSN, while BCG PSN not only accelerates the differentiation in thymus, but also has some direct stimulation to peripheral CD4 +T lymphocytes, and can maintain CD4 +/CD8 + ratio within normal range. So, BCG PSN is safer.
文摘Objective: To study the effect of Thymosin Injection combined with entecavir therapy on the viral load, liver fibrosis and immune response of patients with compensated liver cirrhosis. Methods: Patients who were diagnosed with chronic hepatitis b complicated by compensated liver cirrhosis in our hospital between March 2015 and January 2017 were selected and randomly divided into two groups, observation group received Thymosin Injection combined with entecavir therapy, and control group received entecavir therapy. The viral load, liver function injury indexes, liver fibrosis indexes, immune cytokines and immune cell apoptosis molecules were measured 24 weeks after treatment. Results: 24 weeks after treatment, HBV-DNA copy number in peripheral blood as well as ALT, AST, TBIL, HA, PC-III, LN, C-IV, IL-4, IL-10, TGF-β1, IL-17 and IL-22 levels in serum of observation group was significantly lower than those of control group, and peripheral blood FAS, CYCS, CASP8, CASP9 and CASP3 mRNA expression were significantly lower than those of control group. Conclusion:Thymosin Injection combined with entecavir therapy can reduce viral load, improve liver function, inhibit liver fibrosis and regulate immune function in patients with compensated liver cirrhosis.
